However, a growing number of studies have shown that SFRP2 is associated with metastasis, poor prognosis and treatment resistance in a variety of malignant diseases, including melanoma, prostate cancer and glioma.35, 36, 37, 38, 39. Here, SFRP2 is linked to prostate carcinoma.